Express News | Cytokinetics to Announce Third Quarter Results on November 6, 2024
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Possible Bearish Signals With Cytokinetics Insiders Disposing Stock
Oppenheimer Buy-rated Ideas: BSX, MDT, and One Hold: CYTK
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $72 to $120
Cantor Fitzgerald Reiterates Overweight on Cytokinetics
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $60 to $120
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Cytokinetics Hold Rating: Balancing Promising Commercial Strategy With Execution Risks and Market Uncertainties
Cytokinetics' Strategic Cardiology Franchise Poised for Growth With Aficamten and Expanding Pipeline
Barclays Remains a Buy on Cytokinetics (CYTK)
Cytokinetics: Strategic Growth and Promising Cardiology Pipeline Justify Buy Rating
Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds?
Cytokinetics Will Provide An Update On Cardiac Myosin Modulation Programs And Global Commercial Launch Readiness For Aficamten At Its Investor And Analyst Day Today
Cytokinetics Insider Sold Shares Worth $278,050, According to a Recent SEC Filing
Cytokinetics Inc (CYTK) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $120
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)